# N-3C01 Monotherapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors

> **NCT07639450** · PHASE1,PHASE2 · RECRUITING · sponsor: **Hefei Xinzhu Biological Technology Co., Ltd.** · enrollment: 114 (estimated)

## Conditions studied

- Advanced Malignant Solid Tumors

## Interventions

- **DRUG:** N-3C01(Q2W)
- **DRUG:** N-3C01(Q3W)
- **DRUG:** N-3C01
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT07639450
- **Lead sponsor:** Hefei Xinzhu Biological Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-15
- **Primary completion:** 2028-08-31
- **Final completion:** 2028-09-30
- **Target enrollment:** 114 (ESTIMATED)
- **Last updated:** 2026-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07639450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07639450, "N-3C01 Monotherapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors". Retrieved via MORVS 2026-10-22 from https://api.morvs.ai/clinical/NCT07639450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*